Compare · TXMD vs VTRS
TXMD vs VTRS
Side-by-side comparison of TherapeuticsMD Inc. (TXMD) and Viatris Inc. (VTRS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both TXMD and VTRS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- VTRS is the larger of the two at $23.87B, about 1102.8x TXMD ($21.6M).
- VTRS has been more active in the news (11 items in the past 4 weeks vs 3 for TXMD).
- VTRS has more recent analyst coverage (21 ratings vs 2 for TXMD).
- Company
- TherapeuticsMD Inc.
- Viatris Inc.
- Price
- -
- -
- Market cap
- $21.6M
- $23.87B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 3
- 11
- Recent ratings
- 2
- 21
TherapeuticsMD Inc.
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17Ã-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-007HR and TX-008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Viatris Inc.
Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.
Latest TXMD
- SEC Form 10-Q filed by TherapeuticsMD Inc.
- TherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- TherapeuticsMD Announces Third Quarter 2026 Financial Results
- SEC Form 10-Q filed by TherapeuticsMD Inc.
- TherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- TherapeuticsMD Announces Second Quarter 2026 Financial Results
- SEC Form 10-Q filed by TherapeuticsMD Inc.
- TherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- TherapeuticsMD Announces First Quarter 2026 Financial Results
- Amendment: SEC Form 10-K/A filed by TherapeuticsMD Inc.
Latest VTRS
- Amendment: SEC Form SC TO-T/A filed by Viatris Inc.
- A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End
- Ingram Micro Holding Set to Join S&P SmallCap 600
- Viatris to Participate in Upcoming Investor Conferences
- Amendment: SEC Form SCHEDULE 13G/A filed by Viatris Inc.
- SEC Form 10-Q filed by Viatris Inc.
- Viatris Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Viatris Reports Third-Quarter 2026 Financial Results
- Viatris Announces Quarterly Dividend
- Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.